Shares of Aridis Pharmaceuticals Inc (NASDAQ:ARDS) have earned an average rating of “Buy” from the seven ratings firms that are covering the stock, reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $30.60.

A number of research analysts recently commented on ARDS shares. Maxim Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Aridis Pharmaceuticals in a research report on Monday, April 1st. Northland Securities reaffirmed a “buy” rating and set a $40.00 price objective on shares of Aridis Pharmaceuticals in a research report on Wednesday, April 17th. Finally, Zacks Investment Research raised shares of Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Tuesday, April 2nd.

Aridis Pharmaceuticals stock opened at $9.68 on Friday. The company has a market capitalization of $70.53 million and a PE ratio of -1.38. Aridis Pharmaceuticals has a fifty-two week low of $7.59 and a fifty-two week high of $13.85.

Aridis Pharmaceuticals (NASDAQ:ARDS) last released its earnings results on Tuesday, May 14th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.12). The firm had revenue of $1.02 million during the quarter. Aridis Pharmaceuticals had a negative return on equity of 1,961.31% and a negative net margin of 660.78%. As a group, research analysts predict that Aridis Pharmaceuticals will post -3.11 EPS for the current year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

See Also: Determine Your Level of Risk Tolerance

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with's FREE daily email newsletter.